RxDoctor Payments Data

Aisha Brownlee, APRN

Nurse Practitioner · Palos Heights, ILNPI 1124303383

Payments from drug & device makers

$3,185in general payments, 2019–2025

Across 121 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$389
  • AstraZeneca$320
  • Lilly USA, LLC$187
  • E.r. Squibb & Sons, L.L.C.$176
  • Pfizer$163
  • Takeda Pharmaceuticals U.S.A., Inc.$155
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$2,83689%
  • Education$34911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,185 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$123,352
Medicare patients
184
Services billed
3,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$39,799
XareltoRivaroxaban27$21,679
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$643
Levothyroxine Sodium41$542
Pantoprazole Sodium39$453
Atorvastatin Calcium47$409
Letrozole15$389
Anastrozole23$366
Potassium Chloride24$355
Gabapentin20$287
Metoprolol Tartrate27$242
Amlodipine Besylate37$236
Metoprolol Succinate13$226
Phenazopyridine Hcl11$201
Warfarin Sodium18$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$39,79952 claims
Johnson & JohnsonXarelto$93$21,67927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →